Related references
Note: Only part of the references are listed.Reinventing HCV Treatment: Past and Future Perspectives
Wendy Carter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein
Eric J. Lawitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz et al.
GASTROENTEROLOGY (2016)
OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2016)
C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF GT1-INFECTED PATIENTS WITH 12 WEEKS OF ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN AFTER FAILURE OF SHORT-DURATION ALL-ORAL THERAPY
E. J. Lawitz et al.
JOURNAL OF HEPATOLOGY (2016)
PRECLINICAL PROFILE OF THE PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITOR GS-9857
J. G. Taylor et al.
JOURNAL OF HEPATOLOGY (2015)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
M. P. Curry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
Share Paper
